Mankind Pharma News and Updates

Name: Latest research reports of Mankind Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Mankind Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news on Mankind Pharma from all sources in a single place.

Mankind Pharma Ltd.

16 Oct 2026, 08:50PM

2275.50

-3.07%

Mankind Pharma to acquire 70% stake in Belgium's ACTx for 48 million

Business Line

The deal gives the Indian drugmaker access to experimental treatments targeting blood and lung cancers, strengthening its ambitions in global pharmaceutical research

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

15 Oct 2026, 09:26PM

2275.50

-3.07%

Mankind Pharma to acquire 70% stake in Belgium's ACTx for 48 million

Business Line

The deal gives the Indian drugmaker access to experimental treatments targeting blood and lung cancers, strengthening its ambitions in global pharmaceutical research

Mankind Pharma Ltd. has an average target of 2871.00 from 4 brokers.

Mankind Pharma to acquire 70% in Belgian biotech firm for 48 million

Business Standard | 15 Oct 2026, 08:16PM

Mankind Pharma Ltd.

20 Aug 2026

2275.50

-3.07%

Mankind Pharma signs China pact to market insulin analogues in India

Business Standard

Firm eyes more partnerships with Chinese pharmaceutical companies to expand its in-licensed drug pipeline as it seeks a larger presence in injectable diabetes therapies

Mankind Pharma Ltd. has an average target of 2871.00 from 4 brokers.

Mankind Pharma inks in-licensing pact with China's Chongqing Chenan Biopharmaceutical on two insulin analogues

Business Line | 20 Aug 2026

Mankind Pharma Ltd.

31 Jul 2026

2275.50

-3.07%

Mankind Pharma shares fall 6% despite 30% Q1 PAT growth; here's why

Business Standard

Brokerages said that Mankind Pharma's Consumer Healthcare growth was muted in Q1, impacted by the discontinuation of discounted cash-and-carry sales.

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

31 Jul 2026

2275.50

-3.07%

Secondary sales growth catches up with IPM

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma’s (MANKIND) reported revenue/EBITDA was in line with expectations for 1QFY27. It missed PAT expectations for the quarter, driven by lower other income and a higher tax rate.

Mankind Pharma Ltd. has an average target of 2871.00 from 4 brokers.

Mankind Pharma Ltd.

30 Jul 2026

2275.50

-3.07%

Mankind Pharma Q1 result: Profit rises 29.6% to 568 cr, revenue up 12.9%

Business Standard

Profit before tax rose 42.4 per cent to 769 crore as expenses grew slower than revenue and finance costs declined 35.6 per cent; tax expense more than doubled

Mankind Pharma Ltd. has an average target of 2871.00 from 4 brokers.

Mankind Pharma Ltd.

30 Jul 2026

2275.50

-3.07%

to see Rapid results content

Mankind Pharma Ltd.

20 Jul 2026

2275.50

-3.07%

Mankind Pharma partners with Minerva Academy after Gothia Cup 2026 success

Business Standard

As part of the partnership, Mankind Pharma branding will appear on the jerseys of three Minerva Academy age-group teams throughout the year during competitions in India and overseas

Mankind Pharma Ltd. has an average target of 2871.00 from 4 brokers.

Mankind Pharma Ltd.

07 Jul 2026

2275.50

-3.07%

Broker's Call: Mankind Pharma (Add)

Business Line

InCred Equities

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

02 Jul 2026

2275.50

-3.07%

BatX Energies raises 105 cr in funding round led by IvyCap Ventures

Business Line

The Series A funding round also saw the participation of existing investors Zephyr Peacock, Mankind Pharma Family Office, Excel Industries Family Office and JITO